Systemic treatment of hepatocellular carcinoma: practical issues and perspectives



There is a growing list of medications for hepatocellular carcinoma. During the last two years several clinical trials confirmed survival benefit of multi-kinase angiogenesis inhibitors. As a result of pioneering trials an immune checkpoint inhibitors presented immunotherapy as promising liver cancer treatment option with real opportunity for long-lasting objective responses. This review provides current situation in the field of new therapies of HCC from the point of common medical
practice in searching for optimal first and second line treatment decision in different clinical situations and express an opinion on HCC immunotherapy development.